Your browser doesn't support javascript.
loading
Mechanistic prediction and validation of Brevilin A Therapeutic effects in Lung Cancer.
Wang, Ruixue; Gao, Cuiyun; Yu, Meng; Song, Jialing; Feng, Zhenzhen; Wang, Ruyu; Pan, Huafeng; Liu, Haimeng; Li, Wei; Fan, Xiangzhen.
Afiliação
  • Wang R; Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Gao C; Department of Rehabilitation Medicine, Binzhou Medical University Hospital, Binzhou, Shandong, China.
  • Yu M; School of Rehabilitation Medicine, Binzhou Medical University, Yantai, Shandong, China.
  • Song J; Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Feng Z; Department of Rehabilitation Medicine, Binzhou Medical University Hospital, Binzhou, Shandong, China.
  • Wang R; School of Rehabilitation Medicine, Binzhou Medical University, Yantai, Shandong, China.
  • Pan H; Department of Rehabilitation Medicine, Binzhou Medical University Hospital, Binzhou, Shandong, China.
  • Liu H; School of clinical medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Li W; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Fan X; Department of Rehabilitation Medicine, Binzhou Medical University Hospital, Binzhou, Shandong, China. haimeng1215@126.com.
BMC Complement Med Ther ; 24(1): 214, 2024 Jun 05.
Article em En | MEDLINE | ID: mdl-38840248
ABSTRACT

BACKGROUND:

Traditional Chinese medicine (TCM) has been found widespread application in neoplasm treatment, yielding promising therapeutic candidates. Previous studies have revealed the anti-cancer properties of Brevilin A, a naturally occurring sesquiterpene lactone derived from Centipeda minima (L.) A.Br. (C. minima), a TCM herb, specifically against lung cancer. However, the underlying mechanisms of its effects remain elusive. This study employs network pharmacology and experimental analyses to unravel the molecular mechanisms of Brevilin A in lung cancer.

METHODS:

The Batman-TCM, Swiss Target Prediction, Pharmmapper, SuperPred, and BindingDB databases were screened to identify Brevilin A targets. Lung cancer-related targets were sourced from GEO, Genecards, OMIM, TTD, and Drugbank databases. Utilizing Cytoscape software, a protein-protein interaction (PPI) network was established. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene set enrichment analysis (GSEA), and gene-pathway correlation analysis were conducted using R software. To validate network pharmacology results, molecular docking, molecular dynamics simulations, and in vitro experiments were performed.

RESULTS:

We identified 599 Brevilin A-associated targets and 3864 lung cancer-related targets, with 155 overlapping genes considered as candidate targets for Brevilin A against lung cancer. The PPI network highlighted STAT3, TNF, HIF1A, PTEN, ESR1, and MTOR as potential therapeutic targets. GO and KEGG analyses revealed 2893 enriched GO terms and 157 enriched KEGG pathways, including the PI3K-Akt signaling pathway, FoxO signaling pathway, and HIF-1 signaling pathway. GSEA demonstrated a close association between hub genes and lung cancer. Gene-pathway correlation analysis indicated significant associations between hub genes and the cellular response to hypoxia pathway. Molecular docking and dynamics simulations confirmed Brevilin A's interaction with PTEN and HIF1A, respectively. In vitro experiments demonstrated Brevilin A-induced dose- and time-dependent cell death in A549 cells. Notably, Brevilin A treatment significantly reduced HIF-1α mRNA expression while increasing PTEN mRNA levels.

CONCLUSIONS:

This study demonstrates that Brevilin A exerts anti-cancer effects in treating lung cancer through a multi-target and multi-pathway manner, with the HIF pathway potentially being involved. These results lay a theoretical foundation for the prospective clinical application of Brevilin A.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sesquiterpenos / Simulação de Acoplamento Molecular / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: BMC Complement Med Ther Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sesquiterpenos / Simulação de Acoplamento Molecular / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: BMC Complement Med Ther Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China